Antibiotic use in acne vulgaris and rosacea: Clinical considerations and resistance issues of significance to dermatologists

Cutis

Volumn 82, Issue 2 SUPPL., 2008, Pages 5-12

  Del Rosso, James Q ^a,b,c,d,e   Leyden, James J ^f   Thiboutot, Diane ^g   Webster, Guy F ^h  

^a UNIVERSITY OF NEVADA   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c VALLEY HOSPITAL MEDICAL CENTER   (United States)

^d Mohave Skin and Cancer Clinics   (United States)

^e Las Vegas Skin and Cancer Clinics   (United States)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; ROSACEA;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; ROSACEA;

EID: 51149087253     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. IMS Health. IMS National Prescription Audit Plus TM, 2006.
2. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:133-135.
3. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978:70:51-55.
4. Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology. 1998;196:135-139.
5. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibocterium acnes by subminimal inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol. 1981;104:453-457.
6. Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis. 2005;75(suppl 4):6-11.
7. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
8. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(suppl 6):9-25.
9. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802.
10. Del Rosso JQ. Recently approved systemic therapies for acne vulgaris and rosacea [published correction appears in Cutis. 2007;80:334]. Cutis. 2007:80:113-120.
11. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004:51:499-512.
12. Bikowski JB. Rosacea: a tiered approach to therapy. Cutis. 2000;66(suppl 4):3-6.
13. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998:12:12-26.
14. Walker C, Webster G. The effect of anti-inflammatory dose doxycycline 40 mg once-daily for 9 months on bacterial flora: subset analysis from a multicenter, double-blind, randomized trial. Poster presented at: 26th Anniversary Fall Clinical Dermatology Conference; October 18-21, 2007; Las Vegas, NV.
15. Del Rosso JQ, Bikowski JB. Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial results evaluating the effects of 40 mg doxycycline monohydrate controlled-release capsules in the treatment of rosacea. Poster presented at: American Academy of Dermatology 64th Annual Meeting; March 3-7, 2006; San Francisco, CA. P164.
16. Levy RM, Huang EY, Roling D, et al. Effect of antibiotic use on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139:467-471.
17. Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol. 2005;141: 1132-1136.
18. Adams SJ, Cunliffe WJ, Cooke EM. Long-term antibiotic therapy for acne vulgaris: effects on the bowel flora of patients and their relatives. J Invest Dermatol. 1985;85: 35-37.
19. Miller YW, Eady EA, Lacey RW, et al. Sequential antibiotic therapy for acne promotes carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother. 1996;38:829-837.
20. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148:467-478.
21. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust. 1998;169:259-261.
22. Leyden JJ. Antibiotic resistant acne. Cutis. 1976;17: 593-596.
23. Bowe WP, Hoffstad O, Margolis DJ. Upper respiratory tract infection in household contacts of acne patients. Dermatology. 2007;215:213-218.
24. Leyden JJ, Mc Ginley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8:41-45.
25. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol. 1989;121:51-57.
26. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005;153:395-403.
27. Schlessinger J, Menter A, Gold M, et al; ZIANA Study Group. Clinical safety and efficacy studies of a novel formulation containing 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:607-615.
28. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54: 73-81.
29. Shalita AR, Myers JA, Krochmal L, et al. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol. 2005;4:48-56.
30. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997; 37:590-595.
31. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologie activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117-1133.
32. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis. 2001;67 (suppl 2):21-24.
33. Shalita AR, Rafal ES, Anderson DN, et al. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis. 2003;72:167-172.
34. Del Rosso JQ. Keeping it clean. Skin Aging. 2003;11: 82-88.
35. Del Rosso JQ. Management of truncal acne vulgaris: current perspectives on treatment. Cutis. 2006;77:285-289.
36. Kircik L. Final study results of the efficacy of benzoyl peroxide 8% wash compared to clindamycin phosphate 1% foam, in mild to moderate truncal acne. Poster presented at: American Academy of Dermatology Summer Meeting; August 1-5, 2007; New York, NY. P102.
37. Del Rosso JQ. Study results of benzoyl peroxide 5%/ clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol. 2007;6:616-622.
38. Kircik L. Community-based trial results of combination clindamycin 1%-benzoyl peroxide 5% topical gel plus tretinoin microsphere gel 0.04% or 0.1% or adapalene gel 0.1% in the treatment of moderate to severe acne. Cutis. 2007;80(suppl 1):10-14.
39. Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, doubleblind, randomized parallel-group trial. J Drugs Dermatol. 2006;5:256-261.
40. Del Rosso JQ. Investigator-blinded study results of benzoyl peroxide 5%/clindamycin 1% topical gel used in combination with tretinoin 0.04% microsphere gel versus tretinoin 0.04% microsphere gel monotherapy in the treatment of acne. Poster presented at: American Academy of Dermatology Summer Meeting; August 1-5, 2007; New York, NY. P105.
41. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007;21:747-753.
42. Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris. Arch Dermatol. 2006;142:605-612.
43. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel 0.1% as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006;142: 597-602.
44. do Nascimento LV, Guedes AC, Magalhaes GM, et al. Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% gel (QD) in the treatment of acne vulgaris for 11 weeks. J Dermatolog Treat. 2003;14: 166-171.
45. Pariser DM, Westmoreland P, Morris A, et al. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6: 899-905.
46. Bowman S, Gold M, Nasir A, et al. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol. 2005:4:611-618.
47. Gold MH, Dhawan SS. Efficacy, safety and tolerability of 5% benzoyl peroxide/1% clindamycin gel used with daily facial cleansers in the treatment of acne vulgaris. Poster presented at: 26th Anniversary Fall Clinical Dermatology Conference; October 18-21, 2007; Las Vegas, NV.
48. Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008;158:208-216.
49. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties. J Am Acad Dermatol. 2006;54:258-265.
50. Leyden JJ. Introduction. Cutis. 2006;78(suppl 4):4-5.
51. Fleischer AB Jr, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cuds. 2006;78(suppl 4):21-31.
52. Berger RS. A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. J Clin Pharmacol. 1988;28: 367-370.
53. Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis. 2007:79:430-434.
54. Turowski CB, James WD. The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris. Adv Dermatol. 2007:23:155-163.
55. Amin K, Riddle CC, Aires DJ, et al. Common and alternate oral antibiotic therapies for acne vulgaris: a review. J Drugs Dermatol. 2007;6:873-880.
56. Strauss JS, Krowchuk DP, Leyden JJ. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007:56:651-663.
57. Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004; 14:391-399.
58. Thiboutot D. Versatility of azelaic acid 15% gel in the treatment of inflammatory acne vulgaris. J Drugs Dermatol. 2008;7:13-16.
59. Thiboutot DM, Harper JC, O'Connell K, et al. Improving outcomes through collaboration. Cutis. 2008;81 (suppl 1):26-31.
60. Harper JC. Hormonal therapy for acne using oral contraceptive pills. Semin Cutan Med Surg. 2005;24:103-106.
61. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003;206:57-67.
62. Helms SE, Bredle DL, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997:36:705-710.
63. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46:917-923.
64. Coates P, Vyakrnam S, Ravenscroft JC, et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol. 2005:153:1126-1136.
65. Crawford GH, Pelle MT, James WD. Rosacea: I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004:51:327-341.
66. Romanowicz M, Stephenson JJ, Del Rosso JQ, et al. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol. 2008;7: 41-49.
67. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003:2:234-245.
68. Skidmore R, Kovach R, Walker C. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.
69. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remission of rosacea. Arch Dermatol. 1998:134:679-683.